Joseph Monsonego

Summary

Country: France

Publications

  1. ncbi request reprint [Prevention of cervical cancer: screening, progress and perspectives]
    Joseph Monsonego
    Institut Alfred Fournier, Paris
    Presse Med 36:92-111. 2007
  2. doi request reprint Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine
    J Monsonego
    Institute of the Cervix, Federation Mutualiste Parisienne, 174 rue de Courcelles, 75017 Paris, France
    Vaccine 28:8065-72. 2010
  3. doi request reprint [Prevalence of genotype-specific HPV infection among women in France: implications for screening and vaccination]
    J Monsonego
    institut du col, 174 rue de Courcelles, Paris, France
    Gynecol Obstet Fertil 41:305-13. 2013
  4. doi request reprint Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines
    Joseph Monsonego
    institut du col, Paris, France
    Vaccine 30:5215-21. 2012
  5. doi request reprint Cervical cancer prevention - current perspectives
    J Monsonego
    Institute of the Cervix, Paris, France
    Endocr Dev 22:222-9. 2012
  6. doi request reprint Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study)
    Joseph Monsonego
    Institut of the Cervix, Paris, France
    Gynecol Oncol 125:175-80. 2012
  7. ncbi request reprint EUROGIN 2007 roadmap on cervical cancer prevention
    J Monsonego
    Vaccine 26:A1-3. 2008
  8. doi request reprint [Anal cancer and human papillomaviruses: a perspective based on the cervical cancer model]
    J Monsonego
    Département de colposcopie, FMP Paris, institut du col, Paris, France
    Gynecol Obstet Fertil 38:250-4. 2010
  9. doi request reprint Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study
    Joseph Monsonego
    Institute of the Cervix, Federation Mutualiste Parisienne, Paris, France
    Int J Cancer 129:691-701. 2011
  10. pmc Psychological impact, support and information needs for women with an abnormal Pap smear: comparative results of a questionnaire in three European countries
    Joseph Monsonego
    Institut of the Cervix, 174 rue de Courcelles, 75017 Paris, France
    BMC Womens Health 11:18. 2011

Detail Information

Publications24

  1. ncbi request reprint [Prevention of cervical cancer: screening, progress and perspectives]
    Joseph Monsonego
    Institut Alfred Fournier, Paris
    Presse Med 36:92-111. 2007
    ..The impending availability of prophylactic HPV vaccines, which are expected to provide 70% protection against cervical cancer, will not affect the practice of screening, which must continue...
  2. doi request reprint Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine
    J Monsonego
    Institute of the Cervix, Federation Mutualiste Parisienne, 174 rue de Courcelles, 75017 Paris, France
    Vaccine 28:8065-72. 2010
    ..Furthermore, the implementation of HPV vaccination programmes may benefit the development or awareness of cervical cancer prevention strategies and ultimately reduce the burden of cervical cancer and improve cervical cancer control...
  3. doi request reprint [Prevalence of genotype-specific HPV infection among women in France: implications for screening and vaccination]
    J Monsonego
    institut du col, 174 rue de Courcelles, Paris, France
    Gynecol Obstet Fertil 41:305-13. 2013
    ..To assess human papillomavirus (HPV) prevalence and genotype distribution by age and cervical cytology/histology status among women undergoing routine gynecological examinations, and to discuss the possible impact on preventive strategies...
  4. doi request reprint Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines
    Joseph Monsonego
    institut du col, Paris, France
    Vaccine 30:5215-21. 2012
    ....
  5. doi request reprint Cervical cancer prevention - current perspectives
    J Monsonego
    Institute of the Cervix, Paris, France
    Endocr Dev 22:222-9. 2012
    ..For the sake of completeness, a short update on the evolution of HPV testing in primary screening programs at present and after HPV vaccine introduction has also been included...
  6. doi request reprint Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study)
    Joseph Monsonego
    Institut of the Cervix, Paris, France
    Gynecol Oncol 125:175-80. 2012
    ..To assess the performance of (FDA-approved) APTIMA® HPV Assay (AHPV), Hybrid Capture 2 (HC2), in-house PCR genotyping, and ThinPrep LBC in population-based screening, stratified by three histological gold standards...
  7. ncbi request reprint EUROGIN 2007 roadmap on cervical cancer prevention
    J Monsonego
    Vaccine 26:A1-3. 2008
  8. doi request reprint [Anal cancer and human papillomaviruses: a perspective based on the cervical cancer model]
    J Monsonego
    Département de colposcopie, FMP Paris, institut du col, Paris, France
    Gynecol Obstet Fertil 38:250-4. 2010
    ..Recent data indicate that anti-HPV vaccination has a significant potential in preventing HPV infections, precancerous lesions, and anal cancer in the general population as well as in the high-risk groups...
  9. doi request reprint Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study
    Joseph Monsonego
    Institute of the Cervix, Federation Mutualiste Parisienne, Paris, France
    Int J Cancer 129:691-701. 2011
    ..AHPV assay is both specific and sensitive for the detection of high-grade precancerous lesions and may be considered as an option for routine cervical cancer screening for women over 20 years of age...
  10. pmc Psychological impact, support and information needs for women with an abnormal Pap smear: comparative results of a questionnaire in three European countries
    Joseph Monsonego
    Institut of the Cervix, 174 rue de Courcelles, 75017 Paris, France
    BMC Womens Health 11:18. 2011
    ..We investigated current practices of communicating abnormal Pap results to evaluate women's reactions and determine the sources of information they use subsequently...
  11. ncbi request reprint The new challenges in the prevention of cervical cancer
    J Monsonego
    Vaccine 26:A4-6. 2008
  12. ncbi request reprint [Prevention of cervical cancer (II): prophylactic HPV vaccination, current knowledge, practical procedures and new issues]
    Joseph Monsonego
    Institut Alfred Fournier, Paris
    Presse Med 36:640-66. 2007
    ..Vaccination and screening, which are complementary and synergistic, now constitute the new standards for prevention of this disease...
  13. doi request reprint Linear array genotyping and hybrid capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear
    Joseph Monsonego
    Institut Alfred Fournier, 25 Boulevard St Jacques, 75014 Paris, France
    Int J STD AIDS 19:385-92. 2008
    ..6%) with high NPV (98.9%) in detecting CIN3+ lesions. HPV16 genotyping alone significantly improves SP and PPV of this test in management of women with abnormal cytology...
  14. ncbi request reprint P16(INK4a) immunocytochemistry in liquid-based cytology samples in equivocal Pap smears: added value in management of women with equivocal Pap smear
    Joseph Monsonego
    Alfred Fournier Institute, Paris, France
    Acta Cytol 51:755-66. 2007
    ..To test whether p1l6(INK4a) immunocytochemistry (ICC) in liquid-based cytology (LBC) is useful with colposcopy in abnormal Pap smears...
  15. ncbi request reprint Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear
    Joseph Monsonego
    Institut Alfred Fournier, 25 Boulevard St Jacques, 75014 Paris, France
    Gynecol Oncol 99:160-8. 2005
    ..To assess the performance of a novel PCR-based assay (Roche AMPLICOR HPV test) in detection of cervical pathology as a part of management for abnormal PAP smear (MAPS) and in women participating in cervical cancer screening...
  16. ncbi request reprint Cervical cancer control, priorities and new directions
    Joseph Monsonego
    EUROGIN, Paris, France
    Int J Cancer 108:329-33. 2004
    ..We report the conclusions of the Experts' Meeting at the EUROGIN 2003 conference...
  17. doi request reprint Civil society: a critical new advocate for vaccination in Europe
    Vanina Laurent-Ledru
    MSD, Paris, France
    Vaccine 29:624-8. 2011
    ..The successful implementation and sustainability of future vaccination programs against infections such as HIV will be dependent upon the active participation of civil society to inform, to reassure and to maintain public trust...
  18. pmc Liquid-based cytology for primary cervical cancer screening: a multi-centre study
    J Monsonego
    Institut Alfred Fournier, 25 boulevard Saint Jacques, Paris, 75014, France
    Br J Cancer 84:360-6. 2001
    ..041). The ThinPrep Pap Test is more accurate than the conventional Pap test and has the potential to optimize the effectiveness of primary cervical cancer screening...
  19. ncbi request reprint Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia
    J Monsonego
    Institut Alfred Fournier, Paris, France
    Int J Gynecol Cancer 16:591-8. 2006
    ..High viral load (>100 relative light unit/positive control) was associated with significant disease. HPV DNA testing improves the accuracy of colposcopy in the detection of high-grade CIN in women with ASCUS or LSIL smears...
  20. ncbi request reprint HPV infections and cervical cancer prevention. Priorities and new directions. Highlights of EUROGIN 2004 International Expert Meeting, Nice, France, October 21-23, 2004
    J Monsonego
    EUROGIN, 174 rue de Courcelles, 75017 Paris, France
    Gynecol Oncol 96:830-9. 2005
  21. ncbi request reprint [Colposcopy: the value of HPV testing in clinical practice]
    J Monsonego
    Département de colposcopie, Institut Alfred Fournier, Paris, France
    Gynecol Obstet Fertil 32:62-74. 2004
    ..Therapeutic decisions must not be based solely on the results of HPV DNA testing except in specific cases...
  22. ncbi request reprint Current direction in the prevention of cervical cancer
    J Monsonego
    EUROGIN, Paris, France
    Eur J Gynaecol Oncol 28:433-4. 2007
    ..Vaccination and screening act complementarily and synergistically, and constitute to date the new standards of disease prevention...
  23. ncbi request reprint EUROGIN 2007 patient education conference: sharing experiences and action in cervical cancer prevention--an overview. Part 2
    Sonia Pagliusi
    Centers for Disease Control, Atlanta, USA
    Vaccine 26:A33-6. 2008
  24. doi request reprint Detection of human papillomavirus genotypes among high-risk women: a comparison of hybrid capture and linear array tests
    Joseph Monsonego
    Institut Alfred Fournier Paris, France
    Sex Transm Dis 35:521-7. 2008
    ..To assess the concordance and performance of 2 different assays in detection of human papillomavirus (HPV) genotypes among women with abnormal Pap smear...